Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Agb-Pharma AB is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner in 1 distinct art unit. This focused prosecution profile indicates that the company's current efforts are concentrated on a specific technical challenge or product within the pharmaceutical industry.
The busiest examiner for this portfolio is WELLS, LAUREN QUINLAN, who is handling 1 pending office action. This single action represents the entirety of the company's pending workload at the patent office. Because there is only 1 distinct examiner and 1 distinct art unit involved, the company's strategy is entirely dependent on the interaction with this specific individual.
The 1 pending office action in the Biotechnology & Pharmaceuticals sector requires a precise response tailored to the standards of the 1 distinct art unit. WELLS, LAUREN QUINLAN is the only examiner the company must interface with at this time. This one-to-one relationship between the pending action and the examiner allows for a very focused legal and technical argument.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18722045 | AQUEOUS MELATONIN FORMULATION | WELLS, LAUREN QUINLAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18722045 | AQUEOUS MELATONIN FORMULATION | WELLS, LAUREN QUINLAN | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18722045 | AQUEOUS MELATONIN FORMULATION | WELLS, LAUREN QUINLAN | 1622 | §102§103§112 | Non-Final OA | — | Pending | Jun 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAgb-Pharma AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Lauren Quinlan Wells has the most, with 1 of Agb-Pharma AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
